** Shares of vaccine developer AIM Vaccine 6660.HK jump 11.6% to HK$3.93
** Co expects net loss of 250 mln to 290 mln yuan ($34.54 mln - $40.07 mln) for 2024, compared to net loss of 1.95 bln yuan in 2023, with revenue of 1.25 bln - 1.3 bln yuan as compared to 1.19 bln yuan a year ago
** Says lower net loss due to decrease in the amount of significant asset impairment losses, and an increase in revenue from higher HBV vaccination revenue
** Hang Seng Commerce & Industry Index .HSNC gains 0.9%, Hang Seng Index .HSI rises 1.3%
** Stock down 38.1% YTD
($1 = 7.2376 Chinese yuan renminbi)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。